Latest News for: gsk

Edit

GSK plc (the 'Company') Transaction notification (Form 6-K) (GSK plc)

Public Technologies 11 Feb 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... GSK plc ... CEO, ViiV Healthcare and President, Global Health, GSK ... GSK plc ... About GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
Edit

Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares (Form 6-K) (GSK plc)

Public Technologies 11 Feb 2026
GSK plc ... GSK plc (the 'Company') ... The awards, which were conditional on continued employment with the GSK group, vested on 9 February 2026 ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... About GSK.
Edit

Transaction notification (Form 6-K) (GSK plc)

Public Technologies 11 Feb 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... CEO, ViiV Healthcare and President, Global Health, GSK ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... About GSK ... Find out more at www.gsk.com ... GSK plc ... behalf of GSK plc.
Edit

Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and Sale of Ordinary Shares and American Depositary Shares (Form 6-K) (GSK plc)

Public Technologies 11 Feb 2026
GSK plc ... GSK plc (the 'Company') ... The closing prices of Ordinary Shares and of ADS of GSK plc on 9 February 2026 were £21.59 and $59.01 ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc.
Edit

GSK's RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older (Form 6-K) (GSK plc)

Public Technologies 10 Feb 2026
GSK plc ... GSK's RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older ... GSK plc (LSE/NYSE ... About GSK's RSV vaccine ... This antigen is combined with GSK's proprietary AS01E adjuvant before administration ... About GSK.
Edit

GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older (GSK plc)

Public Technologies 10 Feb 2026
GSK plc (LSE/NYSE ... RSV is estimated to affect more than six million adults aged 60 years and older in China annually, leading to over 350,000 RSV-related hospitalisations.1 About GSK's RSV vaccine ... Find out more at https.//www.gsk.com ... GSK.
Edit

GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older

Pharmiweb 10 Feb 2026
GSK plc (LSE/NYSE. GSK) today announced ... About GSK’s RSV vaccine ... This antigen is combined with GSK’s proprietary AS01E adjuvant before administration ... About GSK ... Find out more at www.gsk.com ... [5] GSK.
Edit

Ichthyosis Market: Rapid Increment Driven by Innovation – DelveInsight | Timber Pharma, Krystal Biotech, GSK, ...

GetNews 09 Feb 2026
The Key Ichthyosis Companies in the market include - Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Timber Pharmcuticals, Crown Laboratories, Inc, and others ... GSK.
Edit

‘Old school’ UK stocks like Lloyds, GSK, and Vodafone are making a huge comeback. Here ...

The Motley Fool 08 Feb 2026
Just look at the share prices of stocks like Lloyds, GSK, and Vodafone – they’re all up double-digit percentages year to date ... This explains the rise in stocks such as Lloyds, GSK, and Vodafone.
Edit

Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD) (Form 6-K) (GSK plc)

Public Technologies 06 Feb 2026
GSK plc ... GSK plc (LSE/NYSE ... Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK, said ... About GSK in respiratory ... About GSK ... Find out more at www.gsk.com. GSK enquiries ... GSK plc ... behalf of GSK plc.
Edit

AdC adopted a non-opposition decision in concentration operation 3/2026 - Bial Portela / Ativos GSK (Portuguese Competition Authority)

Public Technologies 05 Feb 2026
) 05-02-2026. AdC adopted a non-opposition decision in concentration operation 3/2026 - Bial Portela / Ativos GSK ... 1 of article 19 of the Statutes, approved by Decree-Law No ... Case File. Case File.
Edit

FY 2025 results transcript (GSK plc)

Public Technologies 05 Feb 2026
Ladies and gentlemen, a warm welcome to the GSK Full Year 2025 results call ... GSK will maintain the same position ... Also in our hepatology pipeline is GSK'990, an siRNA therapeutic targeting HSD17B13.
Edit

GSK delivers strong 2025 performance and re-affirms long-term outlooks (Form 6-K) (GSK plc)

Public Technologies 04 Feb 2026
GSK plc published this content on February 04, 2026, and is solely responsible ...
Edit

GSK’s Specialty Medicines Drive Solid Results

Wall Street Journal 04 Feb 2026
It posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion ... .
Edit

GSK posts higher profits but indicates sales growth to slow in 2026

Belfast Telegraph 04 Feb 2026
Pharmaceutical giant GSK has ...

Article Search

tools
×
×
×
×